Author:
Dr Takashi Umeyama (JP)
Abstract:
Objectives: Cunninghamella bertholletiae poses a severe threat to immunocompromised patients, emerging as one of the most virulent causative agents of mucormycosis. Additionally, it is identified as a multidrug-resistant filamentous fungus, showing low susceptibility to three antifungal agent classes. With escalating interest in its genetic foundation, mechanisms of action, and diagnostic challenges, our study’s pivotal objective is to delve into factors tied to drug resistance via whole-genome analysis of C. bertholletiae. We endeavor to elucidate these genomic nuances, laying the foundation for improved therapeutics against infections triggered by this pathogen and charting a course for cutting-edge diagnostic and therapeutic modalities.
Methods: We gently extracted genomic DNA from 11 clinical isolates of C. bertholletiae for long-read sequencing. Sequence data was then acquired using the MinION nanopore sequencer—a state-of-the-art, portable long-read sequencer. Subsequent genome assembly employed Flye, distinguished for its exceptional sequence assembly precision. Post-assembly, genes were predicted and annotated with Funannotate, a robust tool tailored for fungal genome annotation.
Results: The genome assembly of 11 clinical isolates resulted in an average of 14 contigs with a genome size of approximately 31 Mb. Gene prediction revealed roughly 9,400 open reading frames (ORFs) in each genome. These significant findings provide a comprehensive genomic framework and a starting point for detailed studies of drug resistance mechanisms and virulence determinants.
Conclusions: Our genome annotation insights will investigate genes pivotal for drug resistance and heightened virulence. We are driven by an overarching vision to morph these genomic revelations into tangible clinical solutions, spurring the introduction of innovative therapeutic and diagnostic instruments. Our endeavor targets augmenting clinical interventions against C. bertholletiae infections, propelling us toward a future with diminished threats from such ailments. Our dedication lies in deciphering the genomic essence of this formidable pathogen, ushering in a new wave of therapeutic and diagnostic breakthroughs against its challenges.
Abstract Number: 48
Conference Year: 2024
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a